Healthcare News

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble...

Total of 618 patients randomized Topline 12-week data expected in Q1 2027 MILAN and MORRISTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...

Seasoned legal executive brings more than 20 years of experience in strategic transactions, corporate governance, finance and corporate legal operations

SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at...

Published data validates ZIP12-mediated zinc signaling as a novel driver of pulmonary vascular remodeling and supports a differentiated therapeutic approach targeting underlying disease biology Phase...

Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral allosteric TYK2 inhibitor, in people with progressive forms of MS Novel brain-penetrant TYK2 inhibitor offers...

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a...

PATCHOGUE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- One of Long Island’s longest-running craft beer celebrations is returning to Main Street. Blue Point Brewing Co., Long Island’s original craft...

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner...